Noven To Present At Upcoming Investor Conferences

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that it is scheduled to present at two upcoming investor conferences. Robert Strauss, Noven’s President, CEO & Chairman, will present at the Thomas Weisel Partners Healthcare Conference in Boston on Friday, September 7th at 10:55 a.m. ET, and at the Bear Stearns 20th Annual Healthcare Conference in New York City on Tuesday, September 11th at 8:00 a.m. ET. The public is invited to listen to the presentations live via webcast at www.noven.com, and a replay will be available for at least two weeks at the same site.

About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, has established itself as a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Its commercialized transdermal products include Vivelle-Dot® (estradiol transdermal system), the most prescribed estrogen patch in the U.S., and Daytrana™ (methylphenidate transdermal system), the first and only patch approved for the treatment of ADHD.

With the acquisition of JDS Pharmaceuticals in August 2007, Noven has become a broader-based specialty pharmaceutical company with the infrastructure, products and category expertise to market and sell products itself, and with a substantially enhanced late-stage product pipeline.

See www.noven.com for additional information.

Contact:
Alina Bowman
Investor Relations Coordinator
305-253-1916